These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3677 related articles for article (PubMed ID: 12748652)

  • 1. Osteoclast differentiation and activation.
    Boyle WJ; Simonet WS; Lacey DL
    Nature; 2003 May; 423(6937):337-42. PubMed ID: 12748652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T; Nakashima T; Hiroshi N; Penninger JM
    Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
    Adamopoulos IE; Wordsworth PB; Edwards JR; Ferguson DJ; Athanasou NA
    Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF; Lie A; Ransjö M
    J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic regulation of osteoclast development and function.
    Teitelbaum SL; Ross FP
    Nat Rev Genet; 2003 Aug; 4(8):638-49. PubMed ID: 12897775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transduction pathways regulating osteoclast differentiation and function.
    Tanaka S; Nakamura I; Inoue J; Oda H; Nakamura K
    J Bone Miner Metab; 2003; 21(3):123-33. PubMed ID: 12720046
    [No Abstract]   [Full Text] [Related]  

  • 8. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
    Kaji H; Kanatani M; Sugimoto T; Chihara K
    Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
    J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S; Nakamura K; Takahasi N; Suda T
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
    Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
    J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors.
    Kwon OH; Lee CK; Lee YI; Paik SG; Lee HJ
    Biochem Biophys Res Commun; 2005 Sep; 335(2):437-46. PubMed ID: 16083856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoclast stimulating and differentiating factors in human cholesteatoma.
    Hamzei M; Ventriglia G; Hagnia M; Antonopolous A; Bernal-Sprekelsen M; Dazert S; Hildmann H; Sudhoff H
    Laryngoscope; 2003 Mar; 113(3):436-42. PubMed ID: 12616193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
    J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
    Ishida M; Amano S
    J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
    J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Osteoporosis induced by immunosuppressant].
    Fukunaga J; Sugahara T
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():740-3. PubMed ID: 15035219
    [No Abstract]   [Full Text] [Related]  

  • 20. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A; Fuson T; Yang X; Kays J; Moxham C; Zartler E; Chandrashekhar S; Galvin RJ
    Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 184.